Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- 30 August 2018
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 379 (9), 811-822
- https://doi.org/10.1056/NEJMoa1803550
Abstract
BACKGROUND Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis in persons who have hemophilia A without factor VIII inhibitors. METHODS We randomly assigned, in a 2: 2: 1 ratio, participants 12 years of age or older who had been receiving episodic treatment with factor VIII to receive a subcutaneous maintenance dose of emicizumab of 1.5 mg per kilogram of body weight per week (group A) or 3.0 mg per kilogram every 2 weeks (group B) or no prophylaxis (group C). The primary end point was the difference in rates of treated bleeding (group A vs. group C and group B vs. group C). Participants who had been receiving factor VIII prophylaxis received emicizumab at a maintenance dose of 1.5 mg per kilogram per week (group D); intraindividual comparisons were performed in those who had participated in a noninterventional study. RESULTS A total of 152 participants were enrolled. The annualized bleeding rate was 1.5 events (95% confidence interval [CI], 0.9 to 2.5) in group A and 1.3 events (95% CI, 0.8 to 2.3) in group B, as compared with 38.2 events (95% CI, 22.9 to 63.8) in group C; thus, the rate was 96% lower in group A and 97% lower in group B (P<0.001 for both comparisons). A total of 56% of the participants in group A and 60% of those in group B had no treated bleeding events, as compared with those in group C, who all had treated bleeding events. In the intraindividual comparison involving 48 participants, emicizumab prophylaxis resulted in an annualized bleeding rate that was 68% lower than the rate with previous factor VIII prophylaxis (P<0.001). The most frequent adverse event was low-grade injection-site reaction. There were no thrombotic or thrombotic microangiopathy events, development of antidrug antibodies, or new development of factor VIII inhibitors. CONCLUSIONS Emicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no prophylaxis among persons with hemophilia A without inhibitors; more than half the participants who received prophylaxis had no treated bleeding events. In an intraindividual comparison, emicizumab therapy led to a significantly lower bleeding rate than previous factor VIII prophylaxis.Funding Information
- F. Hoffmann-La Roche
This publication has 21 references indexed in Scilit:
- The current status of prophylactic replacement therapy in children and adults with haemophiliaBritish Journal of Haematology, 2015
- Thinking about the burden of treatmentBMJ, 2014
- World Medical Association Declaration of HelsinkiJama-Journal Of The American Medical Association, 2013
- Hemophilia A in the third millenniumBlood Reviews, 2013
- A systematic review of patient-reported measures of burden of treatment in three chronic diseasesPatient Related Outcome Measures, 2013
- Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research StudyJournal of Thrombosis and Haemostasis, 2013
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of lifeEuropean Journal of Haematology, 2012
- The Hemophilias — From Royal Genes to Gene TherapyThe New England Journal of Medicine, 2001